JP7478165B2 - ガレクチン－３の低分子阻害剤 - Google Patents

ガレクチン－３の低分子阻害剤 Download PDF

Info

Publication number
JP7478165B2
JP7478165B2 JP2021557333A JP2021557333A JP7478165B2 JP 7478165 B2 JP7478165 B2 JP 7478165B2 JP 2021557333 A JP2021557333 A JP 2021557333A JP 2021557333 A JP2021557333 A JP 2021557333A JP 7478165 B2 JP7478165 B2 JP 7478165B2
Authority
JP
Japan
Prior art keywords
mmol
independently
alkyl
pharma
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527075A5 (https=
JP2022527075A (ja
JPWO2020198266A5 (https=
Inventor
リウ，チュンジアン
エス ユン，デイビッド
ワン，ウェイ
フォン，ジエンシン
エイ エルズワース，ブルース
レゲイロ－レン，アリシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022527075A publication Critical patent/JP2022527075A/ja
Publication of JP2022527075A5 publication Critical patent/JP2022527075A5/ja
Publication of JPWO2020198266A5 publication Critical patent/JPWO2020198266A5/ja
Application granted granted Critical
Publication of JP7478165B2 publication Critical patent/JP7478165B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021557333A 2019-03-26 2020-03-25 ガレクチン－３の低分子阻害剤 Active JP7478165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823684P 2019-03-26 2019-03-26
US62/823,684 2019-03-26
PCT/US2020/024548 WO2020198266A1 (en) 2019-03-26 2020-03-25 Small molecule inhibitors of galectin-3

Publications (4)

Publication Number Publication Date
JP2022527075A JP2022527075A (ja) 2022-05-30
JP2022527075A5 JP2022527075A5 (https=) 2023-03-16
JPWO2020198266A5 JPWO2020198266A5 (https=) 2023-03-16
JP7478165B2 true JP7478165B2 (ja) 2024-05-02

Family

ID=70293127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557333A Active JP7478165B2 (ja) 2019-03-26 2020-03-25 ガレクチン－３の低分子阻害剤

Country Status (7)

Country Link
US (1) US12275719B2 (https=)
EP (1) EP3947407B1 (https=)
JP (1) JP7478165B2 (https=)
KR (1) KR20210143255A (https=)
CN (1) CN113727988A (https=)
ES (1) ES2984075T3 (https=)
WO (1) WO2020198266A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230104190A (ko) * 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
JP2024501010A (ja) * 2020-12-28 2024-01-10 ガレクト バイオテック エービー ガレクチンに対する新規ガラクトシド阻害剤
WO2023118267A1 (en) * 2021-12-22 2023-06-29 Galecto Biotech Ab Novel galactoside inhibitor of galectins
WO2026002250A1 (zh) * 2024-06-28 2026-01-02 上海济煜医药科技股份有限公司 四唑基取代的吡喃半乳糖苷衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113569A1 (en) 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
WO2018011094A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
JP2018503660A (ja) 2015-01-30 2018-02-08 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
WO2018209255A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US9021050B2 (en) 2012-08-31 2015-04-28 Yume, Inc. Network service system and method with off-heap caching
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
JP6844991B2 (ja) 2015-11-10 2021-03-17 サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． ジッパーを有する伸縮性衣類の製法
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113569A1 (en) 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
JP2018503660A (ja) 2015-01-30 2018-02-08 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
WO2018011094A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2018209255A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof

Also Published As

Publication number Publication date
EP3947407A1 (en) 2022-02-09
KR20210143255A (ko) 2021-11-26
CN113727988A (zh) 2021-11-30
US12275719B2 (en) 2025-04-15
WO2020198266A1 (en) 2020-10-01
EP3947407B1 (en) 2024-06-12
US20220185800A1 (en) 2022-06-16
ES2984075T3 (es) 2024-10-28
JP2022527075A (ja) 2022-05-30

Similar Documents

Publication Publication Date Title
US11858918B2 (en) GLP-1R modulating compounds
JP7478165B2 (ja) ガレクチン－３の低分子阻害剤
CN111635408B (zh) 三唑并-嘧啶化合物和其用途
KR102890853B1 (ko) 갈렉틴-3의 소분자 억제제
KR102609431B1 (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
KR20240127910A (ko) Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물
CN112292386B (zh) 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN115109061A (zh) 三环化合物
CN112279837B (zh) 吡嗪化合物和其用途
JP7772718B2 (ja) ガレクチン－３阻害剤
US12275718B2 (en) Small molecule inhibitors of galectin-3
EA050465B1 (ru) Соединения карбокси-бензимидазола, модулирующие glp-1r
HK40074500B (zh) 吡嗪化合物和其用途
HK1231060A1 (en) Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
HK1208439B (zh) 5-氮杂吲唑化合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240416

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240419

R150 Certificate of patent or registration of utility model

Ref document number: 7478165

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150